Viventia Biotech Inc.

Our next Armed Antibodies™ product candidate consist of a monoclonal antibody chosen from our portfolio. Engineered with our proprietary cytotoxic protein. In our pre-clinical testing,

this antibody has shown to bind to distinct antigens found on a variety of solid tumors, such as ovarian, breast, prostate, and lung cancers. We have demonstrated that VB6-845 may have effective cancer cell killing properties in pre-clinical tests. We are currently producing pre-clinical batches of VB6-845 in our manufacturing facility and have completed animal efficacy studies for VB6-845.